In this edition:
ENZARAD: ADT + radiation therapy ± enzalutamide in localised prostate cancer
PRESTO: combined androgen blockade in biochemically relapsed prostate cancer
EMBARK: enzalutamide ± leuprolide in biochemically recurrent prostate cancer
CAPItello-281: capivasertib + abiraterone in PTEN-deficient de novo metastatic HSPC
PSMAddition: 177-Lu-PSMA-617 + ADT + ARPI in PSMA+ metastatic HSPC
ARASAFE: 3-weekly (75mg/m2) vs. 2-weekly (50mg/m2) docetaxel + ADT + darolutamide in metastatic HSPC
AMPLITUDE: patient-reported outcomes of niraparib + abiraterone acetate + prednisone in HRR-altered metastatic HSPC
PETRANHA: saruparib + ARPI in metastatic prostate cancer
MACE risks in STAMPEDE
Prostate radiotherapy in synchronous, metastatic HSP
Please login below to download this issue (PDF)